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The use of serological and virological tests has become essential in the management of hepatitis C virus (HCV) infection 
in order to diagnose infection, guide treatment decisions and assess the virological response to antiviral therapy. 
Virological tools include serological assays for anti-HCV antibody detection and serological determination of the HCV 
genotype, and molecular assays that detect and quantify HCV RNA and determine the HCV genotype. Anti-HCV 
antibody testing and HCV RNA testing are used to diagnose acute and chronic hepatitis C. Only patients with 
detectable HCV RNA should be considered for pegylated interferon alfa and ribavirin therapy and the HCV genotype 
should be systematically determined before treatment, as it determines the indication, the duration of treatment, the 
dose of ribavirin and the virological monitoring procedure. HCV RNA monitoring during therapy is used to tailor 
treatment duration in HCV genotype 1 infection, and molecular assays are used to assess the end-of-treatment and, 
most importantly the sustained virological response, i.e. the endpoint of therapy. 
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1.  INTRODUCTION 
Virological testing has become essential in the 
management of hepatitis C virus (HCV) infection in order 
to diagnose infection, and most importantly guide 
treatment decisions and assess the virological response to 
antiviral therapy.  
2.  VIROLOGICAL TOOLS 
Serological assays 
Anti-HCV antibody detection 
The detection of anti-HCV antibodies in plasma or 
serum is based on the use of third-generation EIAs, that 
detect mixtures of antibodies directed against various 
HCV epitopes. Recombinant antigens are used to capture 
circulating anti-HCV antibodies onto the wells of 
microtiter plates, microbeads, or specific holders adapted 
to closed automated devices. The presence of anti-HCV 
antibodies is revealed by anti-antibodies labeled with an 
enzyme that catalyzes the transformation of a substrate 
into a colored compound. The optical density (OD) ratio 
of the reaction (sample OD/internal control OD) is 
proportional to the amount of antibodies in the serum or 
plasma sample [1]. The specificity of third-generation 
EIAs for anti-HCV is greater than 99% [2]. Their 
sensitivity is more difficult to determine, given the lack of 
a gold standard method, but it is excellent in HCV-
infected immunocompetent patients. EIAs can be fully 
automated and are well adapted to large volume testing. 
Immunoblot tests are nowadays clinically obsolete given 
the good performance of third-generation anti-HCV EIAs 
[3]. 
Serological determination of the HCV genotype 
The HCV genotype can be determined by seeking for 
antibodies directed to genotype-specific HCV epitopes 
with a competitive EIA. The currently available assay 
(Murex HCV serotyping 1-6 HC02, Abbott Laboratories, 
North Chicago, Illinois) identifies the type (1 to 6), but 
does not discriminate among the subtypes, and provides 
interpretable results in approximately 90% of chronically 
infected immunocompetent patients [4]. Mixed serological 
reactivities can be observed that could be related to mixed 
infection although cross-reactivity or recovery from one 
genotype infection and persistence of viremia with 
another genotype cannot be ruled out. 
Detection and quantification of HCV RNA 
Qualitative, non-quantitative HCV RNA detection  
Qualitative detection assays are based on the 
principle of target amplification using either “classic” 
polymerase chain reaction (PCR), “real-time” PCR or 
TMA [5]. HCV RNA is extracted and reverse transcribed 
into a double stranded complementary DNA (cDNA), 
which is subsequently processed into a cyclic enzymatic 
reaction leading to the generation of a large number of 
detectable copies. Double-stranded DNA copies of HCV 
genome are synthesized in PCR-based assays, whereas 
single-stranded RNA copies are generated in TMA. 
Detection of amplified products is achieved by 
hybridizing the produced amplicons onto specific probes 
after the reaction in “classic” PCR or TMA techniques [5]. 
In “real-time” PCR, each round of amplification leads to 
the emission of a fluorescent signal and the number of 
signals per cycle is proportional to the amount of HCV 
RNA in the starting sample [5-7]. Qualitative detection 
assays must detect 50 HCV RNA IU/ml or less, and have 
equal sensitivity for the detection of all HCV genotypes. 
The lower limit of detection of the qualitative, non 
quantitative reverse-transcriptase PCR-based assay 
Amplicor® HCV v2.0, or of its semi-automated version 
Cobas® Amplicor® HCV v2.0 (Roche Molecular Systems, 
Pleasanton, California) is 50 IU/ml, whereas that of the Int. J. Med. Sci. 2006, 3  36
TMA-based assay Versant® HCV RNA Qualitative Assay 
(Bayer HealthCare) is 10 IU/ml (Table 1). Real-time PCR 
assays, which are also able to quantify HCV RNA, have 
lower limits of detection of the order of 5-30 IU/ml when 
they are used as purely qualitative, non-quantitative 
assays. 
Table 1. Characteristics of current HCV RNA assays. RT  : 
reverse transcriptase, PCR : polymerase chain reaction, TMA : 
transcription-mediated amplification, bDNA : “branched DNA“, 
NA : not applicable. *for 0.2 ml or 0.5 ml of plasma analyzed, 
respectively. 
Assay Manufacturer  Technique  Lower  limit 
of detection 
(qualitative 
assay) 
Dynamic 
range of 
quantification 
(quantitative 
assay) 
 
Amplicor® 
HCV v2.0 
 
Roche 
Molecular 
Systems 
 
Manual RT-
PCR 
 
50 IU/ml 
 
NA 
Cobas® 
Amplicor® 
HCV v2.0 
Roche 
Molecular 
Systems 
Semi-
automated 
RT-PCR 
50 IU/ml  NA 
Versant® 
HCV RNA 
Qualitative 
Assay 
Bayer 
HealthCare 
Manual 
TMA 
10 IU/ml  NA 
Amplicor 
HCV 
Monitor® v2.0 
Roche 
Molecular 
Systems 
Manual RT-
PCR 
600 IU/ml  600-500,000 
IU/ml 
Cobas® 
Amplicor 
HCV Monitor 
v2.0 
Roche 
Molecular 
Systems 
Semi-
automated 
RT-PCR 
600 IU/ml  600-500,000 
IU/ml 
LCx HCV 
RNA 
Quantitative 
Assay 
Abbott 
Diagnostic 
Semi-
automated 
RT-PCR 
25 IU/ml  25-2,630,000 
IU/ml 
Versant® 
HCV RNA 3.0 
Assay 
Bayer 
HealthCare 
Semi-
automated 
bDNA 
615 IU/ml  615-7,700,000 
IU/ml 
Cobas® 
TaqMan HCV 
Test 
Roche 
Molecular 
Systems 
Semi-
automated 
real-time 
PCR 
15 IU/ml  43-69,000,000 
IU/ml 
Abbott 
RealTime 
Abbott 
Diagnostic 
Semi-
automated 
real-time 
PCR 
30 IU/ml or 
12 IU/ml* 
12-100,000,000 
IU/ml 
HCV RNA quantification 
HCV RNA can be quantified by means of target 
amplification techniques (competitive PCR or real-time 
PCR) or signal amplification techniques (branched DNA 
(bDNA) assay) [5]. Five standardized assays are 
commercially available. Two of them are based on 
competitive PCR : Amplicor HCV Monitor® v2.0 and its 
semi-automated version Cobas® Amplicor HCV 
Monitor® v2.0 (Roche Molecular Systems), and LCx® 
HCV RNA Quantitative Assay (Abbott Diagnostic); one is 
based on bDNA technology, Versant® HCV RNA 3.0 
Assay (Bayer Healthcare) ; and two are based on real-time 
PCR amplification, Cobas® TaqMan HCV Test, which can 
be coupled with automated extraction in Cobas 
Ampliprep® (Roche Molecular Systems), and Abbott 
RealTime™ HCV assay (Abbott Diagnostics), which uses 
the Abbott m2000 system and can also be coupled with an 
automated extraction procedure. Table 1 shows the 
respective dynamic ranges of quantification of the 
currently available assays, i.e. the HCV RNA intervals 
within which quantification is accurate in the 
corresponding assay. HCV RNA levels falling above the 
upper limit of quantification of the assay are 
underestimated and the samples must be retested after 
1/10 to 1/100 dilution in order to achieve accurate 
quantification. The most promising approach for the 
future is fully automated real-time PCR assays, which are 
faster, more sensitive than classical target amplification 
techniques and are not prone to carryover contamination.  
Molecular determination of the HCV genotype 
(genotyping) 
The reference method for HCV genotype 
determination is direct sequencing of the NS5B or E1 
regions of HCV genome by means of “in-house” 
techniques, followed by sequence alignment with 
prototype sequences and phylogenetic analysis [8, 9]. 
These techniques must be used in molecular epidemiology 
studies, where exact subtyping is needed. In clinical 
practice, HCV genotype can be determined by various 
commercial kits, using direct sequence analysis of the 5’ 
noncoding region (Trugene® 5'NC HCV Genotyping Kit, 
Bayer HealthCare, Diagnostics Division, Tarrytown, New 
York) or reverse hybridization analysis using genotype-
specific probes located in the 5’ noncoding region 
(commercialized as INNO-LiPA HCV II, Innogenetics, 
Ghent, Belgium, or Versant® HCV Genotyping Assay, 
Bayer HealthCare) [10-13]. Mistyping is rare with these 
techniques, but mis-subtyping may occur in 10 to 25% of 
cases, related to the studied region (5’ noncoding region) 
rather than the technique used. These errors have no 
clinical consequences, because only the type is used for 
therapeutic decision-making. An assay based on direct 
sequencing of the NS5B region is currently in 
development (Trugene® NS5B HCV Genotyping Kit, 
Bayer HealthCare). 
3.  DIAGNOSIS OF HCV INFECTION 
Acute hepatitis C 
Patients with a suspicion of acute hepatitis C should 
be tested for both anti-HCV antibodies by EIA and HCV 
RNA with a sensitive technique, i.e. an HCV RNA assay 
with a lower limit of detection of 50 IU/ml or less [1]. 
Four marker profiles can be observed according to the 
presence or absence of either marker. The presence of 
HCV RNA in the absence of anti-HCV antibodies is 
strongly indicative of acute HCV infection, which will be 
confirmed by seroconversion (i.e. the appearance of anti-
HCV antibodies) a few days to weeks later. Acutely 
infected patients can also have both HCV RNA and anti-
HCV antibodies at the time of diagnosis. It is difficult, in 
this case, to distinguish acute hepatitis C from an acute 
exacerbation of chronic hepatitis C or an acute hepatitis of 
another cause in a patient with chronic hepatitis C. Acute 
hepatitis C is very unlikely if both anti-HCV antibodies 
and HCV RNA are absent. It is also unlikely if anti-HCV 
antibodies are present without HCV RNA. These patients 
should however be retested after a few weeks because 
HCV RNA can be temporarily undetectable, due to 
transient, partial control of viral replication by the 
immune response before replication escapes and chronic 
infection establishes [14]. Apart from such cases, the 
presence of anti-HCV antibodies in the absence of HCV 
RNA is generally seen in patients who have recovered 
from a past HCV infection. Nevertheless, this pattern 
cannot be differentiated from a false positive EIA result, 
the exact prevalence of which is unknown.  Int. J. Med. Sci. 2006, 3  37
Chronic hepatitis C 
In patients with clinical or biological signs of chronic 
liver disease, chronic hepatitis C is certain when both anti-
HCV antibodies and HCV RNA (sought for with a 
sensitive technique, detecting 50 IU/ml or less) are 
present [3, 15]. Detectable HCV replication in the absence 
of anti-HCV antibodies is exceptional with the current 
third-generation EIAs, almost exclusively observed in 
profoundly immunodepressed patients, hemodialysis 
patients or agammaglobulinemic subjects [16, 17]. 
In patients who have no indication for therapy or 
have a contra-indication to the use of antiviral drugs, 
virological tests have no prognostic value. Indeed, neither 
anti-HCV antibodies nor the HCV RNA load correlate 
with the severity of liver inflammation or fibrosis nor with 
their progression. Thus, they cannot be used to predict the 
natural course of infection or the onset of extrahepatic 
manifestations. In untreated patients, the severity of liver 
inflammation and fibrosis must be evaluated every three 
to five years by means of a liver biopsy or non-invasive 
serological or ultrasound-based testing [18]. 
4.  MANAGEMENT OF ANTIVIRAL THERAPY 
The current standard treatment for chronic hepatitis 
C is the combination of pegylated interferon (IFN) alfa 
and ribavirin [18]. The efficacy endpoint of hepatitis C 
treatment is the “sustained virological response” (SVR), 
defined by the absence of detectable HCV RNA in serum 
as assessed by an HCV RNA assay with a lower limit of 
detection of 50 IU/ml or less 24 weeks after the end of 
treatment [18].  
Initiation of therapy 
Only patients with detectable HCV RNA should be 
considered for pegylated IFN alfa and ribavirin 
combination therapy [18]. The decision to treat patients 
with chronic hepatitis C depends on multiple parameters, 
including a precise assessment of the severity of liver 
disease and of its foreseeable outcome, the presence of 
absolute or relative contra-indications to therapy, and the 
patient’s willingness to be treated.  
The HCV genotype should be systematically 
determined before treatment, as it determines the 
indication, the duration of treatment, the dose of ribavirin 
and the virological monitoring procedure [19]. 
HCV genotype 1 
Given the likelihood of a sustained virological 
response, of the order of 40% to 50%, a precise assessment 
of liver disease prognosis by means of a liver biopsy or a 
non-invasive method based on serological markers of 
fibrosis or ultrasound-based testing [20, 21] must be 
performed in order to help with the treatment decision 
(Figure 1A). It is recommended not to treat patients with 
mild lesions and to re-assess their liver disease after 3 to 5 
years. The patients with inflammation and/or fibrosis 
(Metavir score A ≥ 2 and/or F ≥ 2) have an indication for 
therapy [18]. 
The approved dose of pegylated IFN alfa-2a is 180 µg 
per week, independent of body weight, whereas that of 
pegylated IFN alfa-2b is weight-adjusted at 1.5 µg/kg per 
week, identical for all HCV genotypes. Patients infected 
with HCV genotype 1 should receive a high dose of 
ribavirin, i.e. 1,000 to 1,200 mg daily, based on body 
weight less than or greater than 75 kg (it has been recently 
suggested that the heaviest patients could even benefit 
from a higher ribavirin dose, up to 1,600 mg daily) and 
they theoretically require 48 weeks of treatment (Figure 
1A) [18]. However, monitoring of HCV RNA load 
decrease during therapy is recommended in order to 
avoid treating for 48 weeks patients with no likelihood of 
an SVR [22, 23]. In this purpose, HCV RNA quantification 
should be performed at baseline and after 12 weeks of 
treatment (Figure 1A) [18]. Both measures must be 
performed with the same technique in order to ensure 
comparability of the results at the two time points. 
Treatment must be continued when there is a 2-log drop 
in HCV RNA level, i.e. when baseline HCV RNA level is 
divided by 100 or more, or when HCV RNA is 
undetectable at week 12 [18]. In these patients, it is 
recommended to assess the presence of HCV RNA with a 
sensitive technique (lower limit of detection : 50 IU/ml or 
less) at week 24. If HCV RNA is undetectable at week 24, 
treatment must be continued until week 48, with a high 
likelihood of an SVR. It was recently suggested that 24 
weeks of therapy might be sufficient for patients with a 
baseline viral load below 600,000 IU/ml in whom 
pegylated IFN alfa-2b-based treatment yields a 2-log 
decline at week 12 and undetectable HCV RNA at week 
24 [24]. In contrast, if HCV RNA is still detectable at week 
24, the likelihood of an SVR is virtually nil and treatment 
can be stopped or continued with the only aim to slow 
liver disease progression in patients with a severe 
prognosis, without any hope to eradicate infection (Figure 
1A) [18, 22]. Ongoing trials are studying whether a 
prolonged antiviral treatment or maintenance therapy 
with pegylated IFN alfa monotherapy could be beneficial 
in the latter patients. When treatment is continued until 
week 48, the end-of-treatment and sustained virological 
responses should be assessed by means of a sensitive 
HCV RNA assay, with a lower limit of detection of 50 
IU/ml or less [18]. HCV RNA detection at the end of 
therapy is highly predictive of a post-treatment relapse, 
whereas the absence of HCV RNA at the end of treatment 
indicates a virological response. These patients must be 
retested for HCV RNA with a sensitive method 24 weeks 
later in order to assess the SVR, i.e. the endpoint of 
therapy [1, 18]. HCV infection appears to be definitively 
cured in the vast majority of sustained virological 
responders. 
The lack of a 12-week virological response (no 
change or an HCV RNA decrease of less than 2 logs at 
week 12) is associated with a virtually nil probability of a 
subsequent sustained virological response [22, 23]. 
Treatment can thus be stopped at week 12 in these 
patients, or continued to slow liver disease progression 
without clearing the virus (Figure 1A). The benefits of 
maintenance therapy on the outcome of HCV-associated 
liver disease are currently under investigation. This 
“stopping rule”, based on monitoring of HCV RNA load 
reduction at week 12, was recently shown to also apply to 
patients co-infected with HCV and human 
immunodeficiency virus [25-27]. Int. J. Med. Sci. 2006, 3  38
Figure 1. Current algorithms for the use of HCV virological tools in the treatment of chronic hepatitis C, according to the HCV 
genotype: genotype 1 (A), genotypes 2 and 3 (B), and genotypes 4, 5 and 6 (C). 
 
 
 Int. J. Med. Sci. 2006, 3  39
HCV genotypes 2 and 3 
Patients infected with HCV genotypes 2 or 3 have a 
70%-80% likelihood of an SVR with a low dose of ribavirin 
and only 24 weeks of treatment [19, 23, 28]. Thus, in the 
absence of contra-indications, these patients should be 
treated regardless of the severity of their liver disease and 
they do not need a liver biopsy of noninvasive assessment 
of liver fibrosis (Figure 1B). The recommended dose of 
pegylated IFN alfa-2a or alfa-2b is the same as for HCV 
genotype 1, i.e. 180 μg/week and 1.5 μg/kg/week, 
respectively. The fixed recommended dose of ribavirin is 
800 mg per day (Figure 1B) [18]. It is possible that even 
lower doses of ribavirin and/or shorter duration of 
treatment could be sufficient to achieve an SVR in certain 
subgroups of patients with genotype 2 or 3 infection, such 
as those with a low baseline viral load and no extensive 
fibrosis or cirrhosis, as suggested by recent preliminary 
data [29]. One should be careful in patients who combine 
several baseline parameters of non-response, such as 
extensive fibrosis, an old age and a male gender, who 
might need 48 weeks of therapy to clear infection. 
No monitoring of HCV RNA level changes during 
therapy is recommended in the patients with genotype 2 
or 3 infection, because the vast majority of them become 
HCV RNA-negative early during treatment. Like in HCV 
genotype 1-infected patients, the virological response 
must be assessed by means of a sensitive HCV RNA assay 
at the end of therapy and 24 weeks later in order to 
determine whether the virological response is sustained 
(Figure 1B) [1, 18]. 
HCV genotypes 4, 5 and 6 
In the absence of any clinical trial including a 
sufficient number of patients, the likelihood of an SVR 
and the optimal treatment schedule remain unknown for 
the patients infected with HCV genotypes 4, 5 or 6. It is 
thus recommended to treat them like those infected with 
HCV genotype 1, i.e. with pegylated IFN alfa at the usual 
dose, combined with a high dose of ribavirin (1000-1200 
mg per day, according to body weight less or greater than 
75 kg) (Figure 1C). In the absence of published data, no 
stopping rules have been defined and it is recommended 
to treat these patients for a total of 48 weeks. The 
virological response must be assessed by means of a 
sensitive HCV RNA assay (lower limit of detection of 50 
IU/ml or less) at the end of therapy and 24 weeks later [1, 
18]. 
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